Abstract: A method is disclosed for treating diseases or disorders involving complement by pulmonary administration of complement inhibitory proteins such as soluble complement receptor type 1 (sCR1). The present invention relates to the direct treatment of certain complement related disorders by administering complement inhibitory proteins via the pulmonary route, in particular, by direct delivery to the lungs by aerosolization of a complement inhibitory protein and subsequent inhalation.
Type:
Grant
Filed:
August 11, 1995
Date of Patent:
January 2, 2001
Assignees:
Avant Immunotherpeutics, Inc., Regents of the University of Minnesota
Inventors:
James L. Levin, Jean F. Regal, Carol A. Toth